Cell and Gene Therapy Market to Reach US$ 105.83 Billion by 2033 at 21.5% CAGR; North America Leads with 42% Share - Key Players: Novartis, Gilead, Bristol Myers Squibb

The Cell and Gene Therapy Market reached US$ 13.90 billion in 2024 and is expected to reach US$ 105.83 billion by 2033, growing at a CAGR of 21.5% during the forecast period 2025-2033. The market is witnessing rapid expansion driven by rising prevalence of genetic disorders, cancer, and rare diseases, along with significant advancements in biotechnology and molecular medicine.

Cell and gene therapies offer transformative treatment approaches by targeting the root causes of disease through genetic modification, cell engineering, and regenerative mechanisms. Innovations in viral and non-viral delivery systems, increasing clinical trial activity, and growing regulatory approvals are accelerating market growth. Additionally, strong investments from pharmaceutical and biotechnology companies, expanding manufacturing capabilities, and supportive regulatory frameworks for advanced therapies are positioning the global cell and gene therapy market for sustained long-term expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cell-and-gene-therapy-market?sai-v

The Cell and Gene Therapy Market encompasses the global research, development, and commercialization of therapies that modify or replace cells and genetic material to treat, prevent, or potentially cure diseases.

Key Developments
✅ December 2025: Global health systems and oncology centers expanded adoption of commercially approved cell and gene therapies for hematologic cancers, rare genetic disorders, and inherited metabolic diseases due to improved long-term outcomes.

✅ October 2025: Regulatory authorities in major markets issued updated frameworks to support accelerated approvals and post-market evidence collection for advanced cell and gene therapies.

✅ September 2025: Biotech firms reported positive data from late-stage clinical trials of next-generation gene editing and CAR-T cell therapy candidates targeting solid tumors and high-unmet-need conditions.

✅ July 2025: Manufacturing innovations, including automated closed-loop production systems and decentralized facility models, improved scalability and reduced costs for cell and gene therapy production.

✅ May 2025: Strategic collaborations were formed between pharmaceutical companies and contract development and manufacturing organizations (CDMOs) to expand cell and gene therapy pipelines and supply chain capabilities.

✅ March 2025: Research partnerships advanced base-editing and prime-editing platforms, enhancing precision gene modification for therapeutic applications in rare diseases.

Mergers & Acquisitions
✅ November 2025: A major global pharmaceutical company acquired a clinical-stage gene therapy biotech to broaden its cell and gene therapy portfolio and strengthen capabilities in gene editing platforms.

✅ August 2025: A leading biotech partnered with a CDMO specializing in viral vector production to scale manufacturing capacity for cell and gene therapies.

✅ June 2025: A healthcare investor group acquired a regenerative medicine company with a diversified pipeline of CAR-T and gene therapy assets to accelerate development and commercialization.

Key Players
Novartis AG | Gilead Sciences, Inc. | Bristol Myers Squibb Company | Vertex Pharmaceuticals Incorporated | Sarepta Therapeutics, Inc. | CSL Behring LLC | Amgen, Inc. | Orchard Therapeutics Group | Krystal Biotech, Inc. | bluebird bio, Inc. | Editas Medicine | Intellia Therapeutics | Rocket Pharmaceuticals | Regenxbio | Affinia Therapeutics | Others

Key Highlights
Novartis AG - Holds a 18.9% share, driven by its leadership in gene and cell therapies, strong regulatory expertise, and commercially approved advanced therapies for rare and genetic diseases.

Gilead Sciences, Inc. - Holds a 15.6% share, supported by its viral vector expertise, oncology and rare disease pipeline, and continued investments in next-generation cell and gene therapy platforms.

Vertex Pharmaceuticals Incorporated - Holds a 13.4% share, leveraging its dominance in cystic fibrosis treatments and strategic expansion into gene-editing and curative therapies.

Bristol Myers Squibb Company - Holds a 11.8% share, recognized for its CAR-T cell therapy portfolio, strong hematology-oncology presence, and advanced cell therapy manufacturing capabilities.

Amgen, Inc. - Holds a 9.7% share, benefiting from biologics leadership, genetic medicine research, and a growing focus on RNA- and gene-based therapeutic approaches.

CSL Behring LLC - Holds a 7.9% share, driven by its plasma-derived therapies, rare disease focus, and expanding investments in gene therapy for hematologic disorders.

Sarepta Therapeutics, Inc. - Holds a 6.8% share, focused on genetic neuromuscular disorders with strong momentum in gene therapy development for Duchenne muscular dystrophy.

bluebird bio, Inc. - Holds a 5.6% share, known for its gene therapies targeting rare genetic and hematologic diseases, supported by long-term clinical data.

Krystal Biotech, Inc. - Holds a 4.7% share, specializing in redosable gene therapies using HSV-based vectors, particularly for dermatological genetic conditions.

Orchard Therapeutics Group - Holds a 3.9% share, concentrating on ex-vivo gene therapies for rare pediatric and inherited metabolic disorders.

Editas Medicine - Holds a 2.1% share, emerging as a key CRISPR-based gene-editing player with programs targeting ocular and genetic diseases.

Intellia Therapeutics - Holds a 1.8% share, advancing in vivo CRISPR therapies with promising clinical-stage data.

Rocket Pharmaceuticals - Holds a 1.5% share, focused on gene therapies for rare pediatric cardiovascular and metabolic disorders.

Regenxbio - Holds a 1.3% share, leveraging its NAV AAV vector platform widely licensed across the gene therapy ecosystem.

Affinia Therapeutics - Holds a 1.0% share, developing next-generation AAV vectors with enhanced tissue targeting and durability.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=cell-and-gene-therapy-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
- Rapid advancements in biotechnology, enabling development of transformative cell and gene therapies for a wide range of genetic, oncologic, and rare diseases.

- Increasing prevalence of chronic and genetic disorders that lack effective conventional treatments, driving demand for curative and personalized therapeutic options.

- Growing investments and funding from government agencies, biopharmaceutical companies, and venture capitalists in cell and gene therapy R&D.

- Supportive regulatory frameworks and expedited approval pathways (e.g., breakthrough therapy designations, fast-track approvals) accelerating market entry of innovative therapies.

- Expanding clinical trial activity globally across diverse therapeutic areas including oncology, neurology, hematology, and metabolic disorders.

- Advancements in gene editing technologies (e.g., CRISPR-Cas9, TALENs) and vector delivery systems enhancing precision, efficacy, and safety profiles.

- Rising adoption of personalized medicine approaches and biomarkers guiding patient selection and therapeutic outcomes.

- Collaborations among academic institutions, biotech firms, and large pharmaceutical companies to co-develop and commercialize novel cell and gene therapies.

Industry Developments
- Approval and launch of novel cell therapies such as CAR-T and TCR-T cell products targeting hematologic malignancies and solid tumors.

- Development of next-generation gene therapies employing improved viral and non-viral delivery systems to enhance tissue targeting and reduce immunogenicity.

- Expansion of gene editing platforms and pipeline candidates addressing inherited genetic disorders (e.g., hemophilia, sickle cell disease, muscular dystrophy).

- Strategic partnerships, licensing agreements, and collaborations to accelerate clinical development and expand geographic reach.

- Increased investment in manufacturing scale-up, automated facilities, and quality control systems to support commercial production and supply chain robustness.

- Mergers and acquisitions among biotechnology and pharmaceutical companies to strengthen cell and gene therapy portfolios and technology capabilities.

- Integration of real-world evidence (RWE), artificial intelligence (AI), and advanced analytics to optimize clinical trial design and post-market surveillance.

Regional Insights
North America - 42% share: "Driven by strong biotech innovation hubs, high R&D investments, favorable regulatory support, extensive clinical trial activity, and presence of key market players."

Europe - 27% share: "Supported by collaborative research networks, regulatory incentives for advanced therapies, growing clinical development, and expanding adoption of gene and cell therapy treatments."

Asia Pacific - 24% share: "Fueled by increasing healthcare investment, expanding biopharmaceutical infrastructure, rising disease burden, and growing focus on cell and gene therapy research."

Latin America - 4% share: "Boosted by improving healthcare systems, growing awareness of advanced therapies, and gradual adoption of cell and gene therapy solutions."

Middle East & Africa - 3% share: "Driven by expanding healthcare modernization, increasing investment in innovative treatments, and emerging rare and chronic disease markets."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cell-and-gene-therapy-market?sai-v

Key Segments

By Therapy Type
Cell therapy holds a significant share, driven by its established use in regenerative medicine, oncology (such as CAR-T cell therapies), and immune modulation, along with expanding clinical adoption. Gene therapy is witnessing rapid growth, supported by advances in viral vector technologies, genome editing, and the potential for long-term or curative treatment outcomes across genetic and rare diseases.

By Application
Oncology represents the largest application segment, driven by strong clinical success of cell and gene therapies in hematologic malignancies and solid tumors. Musculoskeletal conditions account for a notable share, supported by growing use of regenerative cell therapies for cartilage, bone, and tissue repair. Ophthalmology is expanding steadily, driven by successful gene therapies for inherited retinal disorders and ongoing clinical advancements. Blood disorders hold a significant share due to increasing adoption of gene and cell therapies for conditions such as sickle cell disease and thalassemia. Immunodeficiency disorders represent a growing segment, supported by targeted gene correction approaches. Graft-versus-host disease (GVHD) contributes steadily, driven by the use of cellular immunomodulatory therapies. Rare diseases collectively account for a substantial portion of the market, supported by orphan drug incentives, focused R&D investment, and expanding regulatory approvals. Other applications, including metabolic and neurological disorders, further support overall market growth.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.